A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer

Clinical Cancer Research

Volumn 13, Issue 24, 2007, Pages 7296-7304

  Yu, Jian ^a,b   Zhu, Tongyu ^c   Wang, Zhirou ^e   Zhang, Hongyu ^a,b   Qian, Ziliang ^d   Xu, Huili ^a,b   Gao, Baomei ^a,b   Wang, Wei ^a,b   Gu, Lianping ^c   Meng, Jun ^c   Wang, Jina ^c   Feng, Xu ^e   Li, Yixue ^d   Yao, Xuebiao ^f,g   Zhu, Jingde ^a,b,h  

^a SHANGHAI CANCER INSTITUTE   (China)

^b Shanghai Jiao Tong University   (China)

^c FUDAN UNIVERSITY   (China)

^d Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^e Guangxi Cancer Institute   (China)

^f UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^g MOREHOUSE SCHOOL OF MEDICINE   (United States)

^h ZHEJIANG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA MARKER;

ABCC6 GENE; ADULT; ALX4 GENE; ARTICLE; BCL2 GENE; BLADDER CANCER; BMP3B GENE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CCNA1 GENE; CDH13 GENE; CFTR GENE; CHINESE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; DISEASE SEVERITY; DNA METHYLATION; DRM GENE; EPIGENETICS; ETHNIC DIFFERENCE; FEMALE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HPR1 GENE; HUMAN; HUMAN TISSUE; ITGA4 GENE; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MINT1 GENE; MT1A GENE; MYOD1 GENE; NEUROLOGIC DISEASE; ONCOGENE; PRIORITY JOURNAL; RASSF1A GENE; RPRM GENE; RUNX3 GENE; SALL3 GENE; SENSITIVITY AND SPECIFICITY; URINARY TRACT DISEASE; URINE SEDIMENT;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 37549047612     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0861     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Liu J, Xiang Y, Jin F, et al. Cancer statistics in Shanghai, China (1972-1999). Tumor 2004;24:11-3.
3. Eble J, Sauter G, Epstein J, Sesterhenn I. Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization classification of tumours. Lyon (France): IARC Press; 2004. p. 93-109.
4. Amiel GE, Lerner SP. Combining surgery and chemotherapy for invasive bladder cancer: current and future directions. Expert Rev Anticancer Ther 2006;6:281-91.
5. Kitamura H, Tsukamoto T. Early bladder cancer: concept, diagnosis, and management. Int J Clin Oncol 2006;11:28-37.
6. Kriegmair M, Baumgartner R, Knuchel R, Stepp H, Hofstadter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 1996;155:105-9; discussion 9-10.
7. Zaak D, Kriegmair M, Stepp H, et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology 2001;57:690-4.
8. Schneeweiss S, Kriegmair M, Stepp H. Is everything all right if nothing seems wrong? A simple method of assessing the diagnostic value of endoscopic procedures when a gold standard is absent. J Urol 1999;161:1116-9.
9. Wawroschek F, Rathert P. Urine cytology. Urologe A 1995;34:69-75.
10. Schulz WA. Understanding urothelial carcinoma through cancer pathways. Int J Cancer 2006;119:1513-8.
11. Lin J, Dinney CP, Grossman HB, et al. E-cadherin promoter polymorphism (C-160A) and risk of recurrence in patients with superficial bladder cancer. Clin Genet 2006;70:240-5.
12. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005;293:810-6.
13. Grossman HB, Soloway M, Messing E, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006;295:299-305.
14. Feil G, Stenzl A. [Tumor marker tests in bladder cancer]. Actas Urol Esp 2006;30:38-45.
15. Pisitkun T, Johnstone R, Knepper MA. Discovery of urinary biomarkers. Mol Cell Proteomics 2006;5:1760-71.
16. Liu BC, Ehrlich JR. Proteomics approaches to urologic diseases. Expert Rev Proteomics 2006;3:283-96.
17. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-16.
18. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;33 Suppl: 245-54.
19. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321:209-13.
20. Ma Y, Jacobs SB, Jackson-Grusby L, et al. DNA CpG hypomethylation induces heterochromatin reorganization involving the histone variant macroH2A. J Cell Sci 2005;118:1607-16.
21. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003;300:455.
22. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature 1998;395:89-93.
23. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005;2 Suppl 1:S4-11.
24. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
25. Cottrell SE, Laird PW. Sensitive detection of DNA methylation. Ann N Y Acad Sci 2003;983:120-30.
26. Ahrendt SA, Chow JT, Xu LH, et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999;91:332-9.
27. Boland CR. Molecular basis for stool-based DNA tests for colorectal cancer: a primer for clinicians. Rev Gastroenterol Disord 2002;2 Suppl 1:S12-9.
28. Jubb AM, Quirke P, Oates AJ. DNA methylation, a biomarker for colorectal cancer: implications for screening and pathological utility. Ann N Y Acad Sci 2003;983:251-67.
29. Ziegler A, Zangemeister-Wittke U, Stahel RA. Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev 2002;28:255-71.
30. Seifert HH, Schmiemann V, Mueller M, et al. In situ detection of global DNA hypomethylation in exfoliative urine cytology of patients with suspected bladder cancer. Exp Mol Pathol 2007;82:292-7.
31. Pu RT, Laitala LE, Clark DP. Methylation profiling of urothelial carcinoma in bladder biopsy and urine. Acta Cytol 2006;50:499-506.
32. Hoque MO, Begum S, Topaloglu O, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006;98:996-1004.
33. Urakami S, Shiina H, Enokida H, et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res 2006;12:2109-16.
34. Friedrich MG, Weisenberger DJ, Cheng JC, et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 2004;10:7457-65.
35. Yates DR, Rehman I, Meuth M, Cross SS, Hamdy FC, Catto JW. Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene 2006;25:1984-8.
36. Urinary bladder. American Joint Committee on Cancer: AJCC cancer staging manual. 6th ed. New York (NY): Springer; 2002. p. 335-40.
37. Yu J, Ni M, Xu J, et al. Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2002;2:29.
38. Yu J, Zhang HY, Ma ZZ, Lu W, Wang YF, Zhu JD. Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res 2003;13:319-33.
39. Zhu J. The altered DNA methylation pattern and its implications in liver cancer. Cell Res 2005;15:272-80.
40. Yu J, Zhang H, Gu J, et al. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 2004;4:65.
41. Xu XL, Yu J, Zhang HY, et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol 2004;10:3441-54.
42. Ding S, Gong BD, Yu J, et al. Methylation profile of the promoter CpG islands of 14 "drug-resistance" genes in hepatocellular carcinoma. World J Gastroenterol 2004;10:3433-40.
43. Huang J, Zhang X, Zhang M, et al. Up-regulation of DLK1 as an imprinted gene could contribute to human hepatocellular carcinoma. Carcinogenesis 2007;28:1094-103.
44. Zhang J, Yu J, Gu J, et al. A novel protein-DNA interaction involved with the CpG dinucleotide at -30 upstream is linked to the DNA methylation mediated transcription silencing of the MAGE-A1 gene. Cell Res 2004;14:283-94.
45. Das PM, Ramachandran K, Vanwert J, et al. Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol Cancer 2006;5:28.
46. Ushijima T, Nakajima T, Maekita T. DNA methylation as a marker for the past and future. J Gastroenterol 2006;41:401-7.
47. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 2004;10:1887-93.
48. Sathyanarayana UG, Maruyama R, Padar A, et al. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res 2004;64:1425-30.